Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP 4: Semaglutide Withdrawal Study in Obesity
NCT03548987Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2018
- Primary completion
- Feb 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of semaglutide in obesity, Overweight, sponsored by Novo Nordisk. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03548987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548987.